<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00579670</url>
  </required_header>
  <id_info>
    <org_study_id>A1281156</org_study_id>
    <nct_id>NCT00579670</nct_id>
  </id_info>
  <brief_title>Treatment of Schizophrenic Patients With Ziprasidone</brief_title>
  <acronym>TRITON</acronym>
  <official_title>Treatment of Schizophrenic Patients With Geodon; Capsules/Oral Suspension/Solution for Injection (Ziprasidone)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether ziprasidone provides good efficacy and tolerability in the treatment of
      schizophrenic Greek patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sampling Method Details: Non-interventional study (subjects chosen by physician in accordance
      to their usual practice).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Summary of Schizophrenia</measure>
    <time_frame>Baseline</time_frame>
    <description>Stage, symptoms and type of schizophrenia were recorded in addition to demographic and other clinical history data at the Baseline visit. The primary outcome was to assess the participants profile. Some assessments have been included in the Baseline demographics. This outcome presents results for the Summary of Schizophrenia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Metabolic Risk Factors</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Most Frequently Used Concomitant Drug Treatments</measure>
    <time_frame>Baseline</time_frame>
    <description>Most frequently concomitant drug treatments used by &gt;15 participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)</measure>
    <time_frame>Week 12</time_frame>
    <description>CGI-I: 7-point clinician rated scale ranging from 0 (not assessed) to 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>CGI-S: 7-point clinician rated scale to assess severity of subject's current illness state; range: 0 (not assessed) to 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. B = Baseline; F = Final Visit (Week 12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS) - Positive Subscale</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Modified positive subscale: clinician-rated measurement that consists of 30 items, each rated from 1 (absent) to 7 (extreme). Positive subscale (ranging from 4 to 28) taking the sum of the following 4 items: P1, delusions; P2, conceptual disorganization; P3, hallucinatory behavior; and P6, suspiciousness/persecution. Higher scores indicated greater severity of symptoms. The positive subscale total was calculated as the sum of the 4 items in the positive subscale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS - Negative Subscale</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Modified negative subscale: assesses negative symptoms associated with schizophrenia. 7 items make up the Negative scale (eg, blunted affect, emotional withdrawal, poor rapport, and passive/apathetic social withdrawal). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Negative Subscale scores range from 7 to 49. This negative subscale total was calculated as the sum of 4 items in the negative subscale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS - Composite Subscale</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The modified composite subscale total was calculated as the difference of the positive subscale total (7 items; total possible score of 49) and the negative subscale total (7 items; total possible score of 49). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The composite subscale total provided an indication of the level of dominance of the symptoms of one subscale over the symptoms of the other subscale. Higher scores indicated greater severity of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Ability of the Medication to Prevent or Treat Your Condition?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Way the Medication Relieves Your Symptoms?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Amount of Time it Takes the Medication to Start Working?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;As a Result of Taking This Medication, do You Experience Any Side Effects at All?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;How Bothersome Are the Side Effects of the Medication You Take to Treat Your Condition?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;To What Extent do the Side Effects Interfere With Your Physical Health and Ability to Function (ie, Ability to Think Clearly, Stay Awake, Etc)?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;To What Extent do the Side Effects Interfere With Your Mental Function (ie, Ability to Think, Stay Awake, Etc)?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;To What Degree Have Medication Side Effects Affected Your Overall Satisfaction With the Medication?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;How Easy or Difficult is it to Use the Medication in Its Current Form?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;How Easy or Difficult is it to Plan When You Will Use the Medication Each Time?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;How Convenient or Inconvenient is it to Take the Medication as Instructed?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;Overall, How Confident Are You That Taking This Medication is a Good Thing?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;How Certain Are You That the Good Things About Your Medication Outweigh the Bad Things?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering the Question &quot;Taking All Things Into Account, How Satisfied or Dissatisfied Are You With This Medication?&quot;</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Final Visit in Body Weight</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">450</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Ziprasidone 20mg, 40mg, 60mg, 80mg capsules, hard; Ziprasidone 10 mg/ml oral suspension Ziprasidone 20mg/ml powder and solvent for the reconstitution of solution for injection</description>
    <other_name>Geodon, Zeldox</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with schizophrenia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Usual clinical practice of physician

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>12461</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chaidari</city>
        <zip>124 61</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chaidari</city>
        <zip>12461</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chaidari</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Corfu</city>
        <zip>49100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Crete</city>
        <zip>731-00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Giannitsa</city>
        <zip>58100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Haidari</city>
        <zip>12461</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kalamata</city>
        <zip>24100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Katerini</city>
        <zip>60100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kozani</city>
        <zip>50100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kozani</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lamia</city>
        <zip>35100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Larisa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Patra</city>
        <zip>26000</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Patra</city>
        <zip>26001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>564-29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56430</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Volos</city>
        <zip>38222</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281156&amp;StudyName=Treatment%20of%20schizophrenic%20patients%20with%20Ziprasidone</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <results_first_submitted>April 2, 2010</results_first_submitted>
  <results_first_submitted_qc>April 27, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 17, 2010</results_first_posted>
  <last_update_submitted>September 16, 2010</last_update_submitted>
  <last_update_submitted_qc>September 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer Inc</organization>
  </responsible_party>
  <keyword>Ziprasidone in patients with schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The use and dosage of ziprasidone for this Non-interventional Post-Marketing Surveillance study was based on the approved summary of product characteristics (SmPC) document and adjusted solely according to medical and therapeutic necessity.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ziprasidone &lt; 80 mg</title>
          <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
        </group>
        <group group_id="P2">
          <title>Ziprasidone 80 mg to &lt; 120 mg</title>
          <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
        </group>
        <group group_id="P3">
          <title>Ziprasidone 120 mg to &lt; 160 mg</title>
          <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
        </group>
        <group group_id="P4">
          <title>Ziprasidone &gt;= 160 mg</title>
          <description>Ziprasidone 160 mg or greater per day.</description>
        </group>
        <group group_id="P5">
          <title>Ziprasidone Unknown</title>
          <description>Details are unknown.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15">Full Analysis Set (FAS): at least 1 dose study medication and at least 1 efficacy measurement</participants>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="285"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Population: Within SmPC (Started)</title>
              <participants_list>
                <participants group_id="P1" count="15">Within summary of product characteristics (SmPC): FAS subjects who received all doses &quot;Within SmPC&quot;</participants>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="159"/>
                <participants group_id="P5" count="0">&quot;Ziprasidone Unknown&quot; reporting group is not applicable to the Within SmPC population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Population: Within SmPC (Completed)</title>
              <participants_list>
                <participants group_id="P1" count="13">Not Completed (DC): Subject died N=1; Adverse Event (AE) N=1</participants>
                <participants group_id="P2" count="55">DC: Lost to follow-up (LTFU) N=1</participants>
                <participants group_id="P3" count="79">DC: AE N=1; Lack of efficacy N=1; Other unspecified N=1; Withdrawal by subject N=1</participants>
                <participants group_id="P4" count="147">DC: AE N=2; Lack of efficacy N=5; LTFU N=3; Other unspecified N=2</participants>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="84"/>
                <participants group_id="P4" count="263"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ziprasidone &lt; 80 mg</title>
          <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
        </group>
        <group group_id="B2">
          <title>Ziprasidone 80 mg to &lt; 120 mg</title>
          <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
        </group>
        <group group_id="B3">
          <title>Ziprasidone 120 mg to &lt; 160 mg</title>
          <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
        </group>
        <group group_id="B4">
          <title>Ziprasidone &gt;= 160 mg</title>
          <description>Ziprasidone 160 mg or greater per day.</description>
        </group>
        <group group_id="B5">
          <title>Ziprasidone Unknown</title>
          <description>Details are unknown.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="88"/>
            <count group_id="B4" value="285"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="450"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 years through 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="169"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 years through 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="173"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="110"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Schizophrenia Duration</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.9" lower_limit="0" upper_limit="63.1"/>
                    <measurement group_id="B2" value="21.4" lower_limit="0" upper_limit="58.5"/>
                    <measurement group_id="B3" value="16.9" lower_limit="0" upper_limit="52.4"/>
                    <measurement group_id="B4" value="12.8" lower_limit="0" upper_limit="50.3"/>
                    <measurement group_id="B5" value="15.6" lower_limit="0" upper_limit="41.4"/>
                    <measurement group_id="B6" value="15.4" lower_limit="0" upper_limit="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary of Schizophrenia</title>
        <description>Stage, symptoms and type of schizophrenia were recorded in addition to demographic and other clinical history data at the Baseline visit. The primary outcome was to assess the participants profile. Some assessments have been included in the Baseline demographics. This outcome presents results for the Summary of Schizophrenia.</description>
        <time_frame>Baseline</time_frame>
        <population>All subjects randomized to a treatment group were included in the Baseline analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Schizophrenia</title>
          <description>Stage, symptoms and type of schizophrenia were recorded in addition to demographic and other clinical history data at the Baseline visit. The primary outcome was to assess the participants profile. Some assessments have been included in the Baseline demographics. This outcome presents results for the Summary of Schizophrenia.</description>
          <population>All subjects randomized to a treatment group were included in the Baseline analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stage: First episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage: Acute exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage: Chronic, stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="117"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage: Refractory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms: Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="191"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms: Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms: Depressive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms: No predominant symptomatology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type: Catatonic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type: Disorganized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type: Paranoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="148"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type: Residual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type: Undifferentiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type: Schizoaffective disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type: Schizophrenia not otherwise specified (NOS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Metabolic Risk Factors</title>
        <time_frame>Baseline</time_frame>
        <population>All subjects randomized to a treatment group were included in this baseline analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone Total</title>
            <description>Ziprasidone all doses received combined.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Metabolic Risk Factors</title>
          <population>All subjects randomized to a treatment group were included in this baseline analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No metabolic risk factors at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 metabolic risk factors at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 metabolic risk factor at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 metabolic risk factors at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥3 metabolic risk factors at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fasting glucose level (≥110 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides (≥150 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL (men &lt;40 mg/dL; women &lt;50 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood pressure (≥130/85 mm Hg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Centrally distributed obesity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Most Frequently Used Concomitant Drug Treatments</title>
        <description>Most frequently concomitant drug treatments used by &gt;15 participants.</description>
        <time_frame>Baseline</time_frame>
        <population>All subjects randomized to a treatment group were included in this baseline analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Most Frequently Used Concomitant Drug Treatments</title>
          <description>Most frequently concomitant drug treatments used by &gt;15 participants.</description>
          <population>All subjects randomized to a treatment group were included in this baseline analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Akineton</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aloperidine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biperiden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clozapine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haloperidol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lorazepam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Olanzapine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quetiapine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Risperidone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tavor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)</title>
        <description>CGI-I: 7-point clinician rated scale ranging from 0 (not assessed) to 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.</description>
        <time_frame>Week 12</time_frame>
        <population>The Full Analysis Set (FAS) - all subjects who received at least 1 dose of study medication and have at least 1 efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)</title>
          <description>CGI-I: 7-point clinician rated scale ranging from 0 (not assessed) to 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.</description>
          <population>The Full Analysis Set (FAS) - all subjects who received at least 1 dose of study medication and have at least 1 efficacy measurement.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="60"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="105"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S)</title>
        <description>CGI-S: 7-point clinician rated scale to assess severity of subject's current illness state; range: 0 (not assessed) to 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. B = Baseline; F = Final Visit (Week 12)</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS; Baseline Visit: 1 subject in the Ziprasidone &gt;=160mg group had missing severity result. Final Visit: 2 subjects (1 subject in the Ziprasidone 120mg to &lt;160mg and 1 subject in the Ziprasidone &lt;80mg group) had missing severity results.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasodone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S)</title>
          <description>CGI-S: 7-point clinician rated scale to assess severity of subject's current illness state; range: 0 (not assessed) to 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. B = Baseline; F = Final Visit (Week 12)</description>
          <population>FAS; Baseline Visit: 1 subject in the Ziprasidone &gt;=160mg group had missing severity result. Final Visit: 2 subjects (1 subject in the Ziprasidone 120mg to &lt;160mg and 1 subject in the Ziprasidone &lt;80mg group) had missing severity results.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B - Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F (only) - Normal, not at all ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Borderline mentally ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Borderline mentally ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Mildly ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Mildly ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="90"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Moderately ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Moderately ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Markedly ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="108"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Markedly ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Severely ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="71"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Severely ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Among the most extremely ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Among the most extremely ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Syndrome Scale (PANSS) - Positive Subscale</title>
        <description>Modified positive subscale: clinician-rated measurement that consists of 30 items, each rated from 1 (absent) to 7 (extreme). Positive subscale (ranging from 4 to 28) taking the sum of the following 4 items: P1, delusions; P2, conceptual disorganization; P3, hallucinatory behavior; and P6, suspiciousness/persecution. Higher scores indicated greater severity of symptoms. The positive subscale total was calculated as the sum of the 4 items in the positive subscale.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Syndrome Scale (PANSS) - Positive Subscale</title>
          <description>Modified positive subscale: clinician-rated measurement that consists of 30 items, each rated from 1 (absent) to 7 (extreme). Positive subscale (ranging from 4 to 28) taking the sum of the following 4 items: P1, delusions; P2, conceptual disorganization; P3, hallucinatory behavior; and P6, suspiciousness/persecution. Higher scores indicated greater severity of symptoms. The positive subscale total was calculated as the sum of the 4 items in the positive subscale.</description>
          <population>FAS</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="4.12"/>
                    <measurement group_id="O2" value="14.4" spread="4.35"/>
                    <measurement group_id="O3" value="14.6" spread="4.82"/>
                    <measurement group_id="O4" value="16.6" spread="5.28"/>
                    <measurement group_id="O5" value="12.6" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="3.60"/>
                    <measurement group_id="O2" value="11.2" spread="4.35"/>
                    <measurement group_id="O3" value="10.5" spread="4.41"/>
                    <measurement group_id="O4" value="10.4" spread="4.92"/>
                    <measurement group_id="O5" value="7.8" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PANSS - Negative Subscale</title>
        <description>Modified negative subscale: assesses negative symptoms associated with schizophrenia. 7 items make up the Negative scale (eg, blunted affect, emotional withdrawal, poor rapport, and passive/apathetic social withdrawal). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Negative Subscale scores range from 7 to 49. This negative subscale total was calculated as the sum of 4 items in the negative subscale.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>PANSS - Negative Subscale</title>
          <description>Modified negative subscale: assesses negative symptoms associated with schizophrenia. 7 items make up the Negative scale (eg, blunted affect, emotional withdrawal, poor rapport, and passive/apathetic social withdrawal). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Negative Subscale scores range from 7 to 49. This negative subscale total was calculated as the sum of 4 items in the negative subscale.</description>
          <population>FAS</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="4.69"/>
                    <measurement group_id="O2" value="16.1" spread="4.05"/>
                    <measurement group_id="O3" value="14.6" spread="5.30"/>
                    <measurement group_id="O4" value="14.7" spread="5.70"/>
                    <measurement group_id="O5" value="12.8" spread="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="4.27"/>
                    <measurement group_id="O2" value="12.8" spread="4.67"/>
                    <measurement group_id="O3" value="11.3" spread="4.78"/>
                    <measurement group_id="O4" value="10.6" spread="5.05"/>
                    <measurement group_id="O5" value="8.6" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PANSS - Composite Subscale</title>
        <description>The modified composite subscale total was calculated as the difference of the positive subscale total (7 items; total possible score of 49) and the negative subscale total (7 items; total possible score of 49). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The composite subscale total provided an indication of the level of dominance of the symptoms of one subscale over the symptoms of the other subscale. Higher scores indicated greater severity of symptoms.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>PANSS - Composite Subscale</title>
          <description>The modified composite subscale total was calculated as the difference of the positive subscale total (7 items; total possible score of 49) and the negative subscale total (7 items; total possible score of 49). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The composite subscale total provided an indication of the level of dominance of the symptoms of one subscale over the symptoms of the other subscale. Higher scores indicated greater severity of symptoms.</description>
          <population>FAS</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="3.57"/>
                    <measurement group_id="O2" value="-1.7" spread="4.86"/>
                    <measurement group_id="O3" value="0.0" spread="5.14"/>
                    <measurement group_id="O4" value="1.9" spread="6.83"/>
                    <measurement group_id="O5" value="-0.2" spread="6.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="2.82"/>
                    <measurement group_id="O2" value="-1.5" spread="3.92"/>
                    <measurement group_id="O3" value="-0.7" spread="3.60"/>
                    <measurement group_id="O4" value="-0.2" spread="4.57"/>
                    <measurement group_id="O5" value="-0.8" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Ability of the Medication to Prevent or Treat Your Condition?&quot;</title>
        <time_frame>Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Ability of the Medication to Prevent or Treat Your Condition?&quot;</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="69"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="102"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Way the Medication Relieves Your Symptoms?&quot;</title>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Way the Medication Relieves Your Symptoms?&quot;</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="86"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Amount of Time it Takes the Medication to Start Working?&quot;</title>
        <time_frame>Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Amount of Time it Takes the Medication to Start Working?&quot;</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;As a Result of Taking This Medication, do You Experience Any Side Effects at All?&quot;</title>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;As a Result of Taking This Medication, do You Experience Any Side Effects at All?&quot;</title>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="189"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;How Bothersome Are the Side Effects of the Medication You Take to Treat Your Condition?&quot;</title>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Bothersome Are the Side Effects of the Medication You Take to Treat Your Condition?&quot;</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely Bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat Bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Little Bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not At All Bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;To What Extent do the Side Effects Interfere With Your Physical Health and Ability to Function (ie, Ability to Think Clearly, Stay Awake, Etc)?&quot;</title>
        <time_frame>Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;To What Extent do the Side Effects Interfere With Your Physical Health and Ability to Function (ie, Ability to Think Clearly, Stay Awake, Etc)?&quot;</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A great deal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quite a bit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;To What Extent do the Side Effects Interfere With Your Mental Function (ie, Ability to Think, Stay Awake, Etc)?&quot;</title>
        <time_frame>Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;To What Extent do the Side Effects Interfere With Your Mental Function (ie, Ability to Think, Stay Awake, Etc)?&quot;</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A great deal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quite a bit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;To What Degree Have Medication Side Effects Affected Your Overall Satisfaction With the Medication?&quot;</title>
        <time_frame>Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;To What Degree Have Medication Side Effects Affected Your Overall Satisfaction With the Medication?&quot;</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A great deal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quite a bit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;How Easy or Difficult is it to Use the Medication in Its Current Form?&quot;</title>
        <time_frame>Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Easy or Difficult is it to Use the Medication in Its Current Form?&quot;</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="117"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="71"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;How Easy or Difficult is it to Plan When You Will Use the Medication Each Time?&quot;</title>
        <time_frame>Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Easy or Difficult is it to Plan When You Will Use the Medication Each Time?&quot;</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="57"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="108"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;How Convenient or Inconvenient is it to Take the Medication as Instructed?&quot;</title>
        <time_frame>Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Convenient or Inconvenient is it to Take the Medication as Instructed?&quot;</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely inconvenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very inconvenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconvenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="71"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="111"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;Overall, How Confident Are You That Taking This Medication is a Good Thing?&quot;</title>
        <time_frame>Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;Overall, How Confident Are You That Taking This Medication is a Good Thing?&quot;</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="88"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;How Certain Are You That the Good Things About Your Medication Outweigh the Bad Things?&quot;</title>
        <time_frame>Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Certain Are You That the Good Things About Your Medication Outweigh the Bad Things?&quot;</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="81"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="101"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering the Question &quot;Taking All Things Into Account, How Satisfied or Dissatisfied Are You With This Medication?&quot;</title>
        <time_frame>Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;Taking All Things Into Account, How Satisfied or Dissatisfied Are You With This Medication?&quot;</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Continuing Treatment With Ziprasidone Following Completion of the Observation Period</title>
        <time_frame>Week 12</time_frame>
        <population>FAS. Four subjects did not answer the question of continuation of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Continuing Treatment With Ziprasidone Following Completion of the Observation Period</title>
          <population>FAS. Four subjects did not answer the question of continuation of treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="245"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Final Visit in Body Weight</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Safety population = all subjects who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 milligrams (mg) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone &gt;= 160 mg</title>
            <description>Ziprasidone 160 mg or greater per day.</description>
          </group>
          <group group_id="O5">
            <title>Ziprasidone Unknown</title>
            <description>Details are unknown.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Final Visit in Body Weight</title>
          <population>Safety population = all subjects who received at least 1 dose of study medication.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="285"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="5.79"/>
                    <measurement group_id="O2" value="-0.2" spread="3.67"/>
                    <measurement group_id="O3" value="-1.0" spread="3.08"/>
                    <measurement group_id="O4" value="0.1" spread="4.70"/>
                    <measurement group_id="O5" value="-1.0" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I): Within Summary of Product Characteristics Population (SmPC)</title>
        <description>CGI-I: 7-point clinician rated scale ranging from 0 (not assessed) to 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.</description>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC population: participants in FAS population who received all doses within SmPC. Within SmPC defined as all PO doses up to and including 160 mg per day and all IM doses up to and including 40 mg per day.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I): Within Summary of Product Characteristics Population (SmPC)</title>
          <description>CGI-I: 7-point clinician rated scale ranging from 0 (not assessed) to 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.</description>
          <population>Within SmPC population: participants in FAS population who received all doses within SmPC. Within SmPC defined as all PO doses up to and including 160 mg per day and all IM doses up to and including 40 mg per day.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S): Within SmPC</title>
        <description>CGI-S: 7-point clinician rated scale to assess severity of subject's current illness state; range: 0 (not assessed) to 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. B = Baseline; F = Final Visit (Week 12)</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Within SmPC</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S): Within SmPC</title>
          <description>CGI-S: 7-point clinician rated scale to assess severity of subject's current illness state; range: 0 (not assessed) to 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. B = Baseline; F = Final Visit (Week 12)</description>
          <population>Within SmPC</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B - Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F (only) - Normal, not at all ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Borderline mentally ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Borderline mentally ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Mildly ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Mildly ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Moderately ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Moderately ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Markedly ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Markedly ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Severely ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Severely ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Among the most extremely ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F - Among the most extremely ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Positive and Negative Syndrome Scale (PANSS) - Positive Subscale: Within SmPC</title>
        <description>Modified positive subscale: clinician-rated measurement that consists of 30 items, each rated from 1 (absent) to 7 (extreme). Positive subscale (ranging from 4 to 28) taking the sum of the following 4 items: P1, delusions; P2, conceptual disorganization; P3, hallucinatory behavior; and P6, suspiciousness/persecution. Higher scores indicated greater severity of symptoms. The positive subscale total was calculated as the sum of the 4 items in the positive subscale.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Syndrome Scale (PANSS) - Positive Subscale: Within SmPC</title>
          <description>Modified positive subscale: clinician-rated measurement that consists of 30 items, each rated from 1 (absent) to 7 (extreme). Positive subscale (ranging from 4 to 28) taking the sum of the following 4 items: P1, delusions; P2, conceptual disorganization; P3, hallucinatory behavior; and P6, suspiciousness/persecution. Higher scores indicated greater severity of symptoms. The positive subscale total was calculated as the sum of the 4 items in the positive subscale.</description>
          <population>Within SmPC; N=participants with evaluable data at observation</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="4.12"/>
                    <measurement group_id="O2" value="14.5" spread="4.37"/>
                    <measurement group_id="O3" value="14.8" spread="4.85"/>
                    <measurement group_id="O4" value="15.3" spread="5.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="3.60"/>
                    <measurement group_id="O2" value="11.3" spread="4.38"/>
                    <measurement group_id="O3" value="10.7" spread="4.47"/>
                    <measurement group_id="O4" value="10.0" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>PANSS - Negative Subscale: Within SmPC</title>
        <description>Modified negative subscale: assesses negative symptoms associated with schizophrenia. 7 items make up the Negative scale (eg, blunted affect, emotional withdrawal, poor rapport, and passive/apathetic social withdrawal). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Negative Subscale scores range from 7 to 49. This negative subscale total was calculated as the sum of 4 items in the negative subscale.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>PANSS - Negative Subscale: Within SmPC</title>
          <description>Modified negative subscale: assesses negative symptoms associated with schizophrenia. 7 items make up the Negative scale (eg, blunted affect, emotional withdrawal, poor rapport, and passive/apathetic social withdrawal). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Negative Subscale scores range from 7 to 49. This negative subscale total was calculated as the sum of 4 items in the negative subscale.</description>
          <population>Within SmPC; N=participants with evaluable data at observation</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="4.69"/>
                    <measurement group_id="O2" value="16.0" spread="4.06"/>
                    <measurement group_id="O3" value="14.8" spread="5.22"/>
                    <measurement group_id="O4" value="14.5" spread="5.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="4.27"/>
                    <measurement group_id="O2" value="12.7" spread="4.71"/>
                    <measurement group_id="O3" value="11.4" spread="4.76"/>
                    <measurement group_id="O4" value="11.1" spread="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>PANSS - Composite Subscale: Within SmPC</title>
        <description>The modified composite subscale total was calculated as the difference of the positive subscale total (7 items; total possible score of 49) and the negative subscale total (7 items; total possible score of 49). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The composite subscale total provided an indication of the level of dominance of the symptoms of one subscale over the symptoms of the other subscale. Higher scores indicated greater severity of symptoms.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>PANSS - Composite Subscale: Within SmPC</title>
          <description>The modified composite subscale total was calculated as the difference of the positive subscale total (7 items; total possible score of 49) and the negative subscale total (7 items; total possible score of 49). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The composite subscale total provided an indication of the level of dominance of the symptoms of one subscale over the symptoms of the other subscale. Higher scores indicated greater severity of symptoms.</description>
          <population>Within SmPC; N=participants with evaluable data at observation</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="3.57"/>
                    <measurement group_id="O2" value="-1.5" spread="4.80"/>
                    <measurement group_id="O3" value="0.0" spread="5.09"/>
                    <measurement group_id="O4" value="0.7" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="2.82"/>
                    <measurement group_id="O2" value="-1.5" spread="3.91"/>
                    <measurement group_id="O3" value="-0.6" spread="3.58"/>
                    <measurement group_id="O4" value="-1.1" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Ability of the Medication to Prevent or Treat Your Condition?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Ability of the Medication to Prevent or Treat Your Condition?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Way the Medication Relieves Your Symptoms?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Way the Medication Relieves Your Symptoms?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Amount of Time it Takes the Medication to Start Working?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Satisfied or Dissatisfied Are You With the Amount of Time it Takes the Medication to Start Working?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;As a Result of Taking This Medication, do You Experience Any Side Effects at All?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;As a Result of Taking This Medication, do You Experience Any Side Effects at All?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;How Bothersome Are the Side Effects of the Medication You Take to Treat Your Condition?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Bothersome Are the Side Effects of the Medication You Take to Treat Your Condition?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely Bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat Bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Little Bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not At All Bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;To What Extent do the Side Effects Interfere With Your Physical Health and Ability to Function (ie, Ability to Think Clearly, Stay Awake, Etc)?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;To What Extent do the Side Effects Interfere With Your Physical Health and Ability to Function (ie, Ability to Think Clearly, Stay Awake, Etc)?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A great deal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quite a bit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;To What Extent do the Side Effects Interfere With Your Mental Function (ie, Ability to Think, Stay Awake, Etc)?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;To What Extent do the Side Effects Interfere With Your Mental Function (ie, Ability to Think, Stay Awake, Etc)?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A great deal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quite a bit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;To What Degree Have Medication Side Effects Affected Your Overall Satisfaction With the Medication?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;To What Degree Have Medication Side Effects Affected Your Overall Satisfaction With the Medication?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A great deal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quite a bit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;How Easy or Difficult is it to Use the Medication in Its Current Form?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Easy or Difficult is it to Use the Medication in Its Current Form?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;How Easy or Difficult is it to Plan When You Will Use the Medication Each Time?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Easy or Difficult is it to Plan When You Will Use the Medication Each Time?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;How Convenient or Inconvenient is it to Take the Medication as Instructed?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Convenient or Inconvenient is it to Take the Medication as Instructed?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely inconvenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very inconvenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconvenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;Overall, How Confident Are You That Taking This Medication is a Good Thing?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;Overall, How Confident Are You That Taking This Medication is a Good Thing?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;How Certain Are You That the Good Things About Your Medication Outweigh the Bad Things?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;How Certain Are You That the Good Things About Your Medication Outweigh the Bad Things?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Answering the Question &quot;Taking All Things Into Account, How Satisfied or Dissatisfied Are You With This Medication?&quot;: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering the Question &quot;Taking All Things Into Account, How Satisfied or Dissatisfied Are You With This Medication?&quot;: Within SmPC</title>
          <population>Within SmPC; N=participants with evaluable data for specified question at observation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percent Change From Baseline to Final Visit in Body Weight: Within SmPC</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Within SmPC</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Final Visit in Body Weight: Within SmPC</title>
          <population>Within SmPC</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="5.79"/>
                    <measurement group_id="O2" value="-0.2" spread="3.67"/>
                    <measurement group_id="O3" value="-1.1" spread="2.75"/>
                    <measurement group_id="O4" value="-0.0" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Continuing Treatment With Ziprasidone Following Completion of the Observation Period: Within SmPC</title>
        <time_frame>Week 12</time_frame>
        <population>Within SmPC</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone &lt; 80 mg</title>
            <description>Ziprasidone up to 80 mg orally (PO) per day or up to 40 mg intramuscularly (IM) per day.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone 80 mg to &lt; 120 mg</title>
            <description>Ziprasidone between 80 mg and &lt; 120 mg PO per day.</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone 120 mg to &lt; 160 mg</title>
            <description>Ziprasidone between 120 mg and &lt; 160 mg PO per day.</description>
          </group>
          <group group_id="O4">
            <title>Ziprasidone = 160 mg</title>
            <description>Ziprasidone 160 mg PO per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Continuing Treatment With Ziprasidone Following Completion of the Observation Period: Within SmPC</title>
          <population>Within SmPC</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ziprasidone &lt; 80 mg</title>
          <description>Ziprasidone up to 80 mg per day.</description>
        </group>
        <group group_id="E2">
          <title>Ziprasidone 80 mg to &lt; 120 mg</title>
          <description>Ziprasidone between 80 mg and &lt; 120 mg per day.</description>
        </group>
        <group group_id="E3">
          <title>Ziprasidone 120 mg to &lt; 160 mg</title>
          <description>Ziprasidone between 120 mg and &lt; 160 mg per day.</description>
        </group>
        <group group_id="E4">
          <title>Ziprasidone &gt;=160 mg</title>
          <description>Ziprasidone 160 mg or greater per day.</description>
        </group>
        <group group_id="E5">
          <title>Ziprasidone Unknown</title>
          <description>Details are unknown.</description>
        </group>
        <group group_id="E6">
          <title>Within SmPC Ziprasidone &lt; 80 mg</title>
          <description>Within SmPC &lt; 80 mg per day; defined as all participants in the FAS population who had PO doses up to 80 mg per day and all IM doses up to and including 40 mg per day.</description>
        </group>
        <group group_id="E7">
          <title>Within SmPC Ziprasidone 80 to &lt; 120 mg</title>
          <description>Within SmPC Ziprasidone 80 to &lt; 120 mg; defined as all participants in the FAS population who had PO doses between 80 mg and &lt; 120 mg per day.</description>
        </group>
        <group group_id="E8">
          <title>Within SmPC Ziprasidone 120 to &lt; 160 mg</title>
          <description>Within SmPC Ziprasidone 120 to &lt; 160 mg; defined as all participants in the FAS population who had PO doses between 120 mg and &lt; 160 mg per day.</description>
        </group>
        <group group_id="E9">
          <title>Within SmPC Ziprasidone = 160 mg</title>
          <description>Within SmPC Ziprasidone = 160 mg; defined as all participants in the FAS population who had PO doses = 160 mg per day.</description>
        </group>
        <group group_id="E10">
          <title>Above SmPC Ziprasidone &gt; 160 mg</title>
          <description>Above SmPC Ziprasidone &gt; 160 mg per day; defined as all participants in FAS population who received at least 1 PO dose above 160 mg per day or any IM dose above 40 mg per day or with an unknown dose or formulation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="285"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E9" subjects_affected="19" subjects_at_risk="159"/>
                <counts group_id="E10" subjects_affected="17" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="285"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="285"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="285"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="159"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Additional descriptive tables were identified as required after review of the originally planned study tables; many subjects included in the tables had received ziprasidone doses above those specified in the summary of product characteristics (SmPC).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

